[go: up one dir, main page]

WO2016054520A3 - Engineered cell surface proteins and uses thereof - Google Patents

Engineered cell surface proteins and uses thereof Download PDF

Info

Publication number
WO2016054520A3
WO2016054520A3 PCT/US2015/053745 US2015053745W WO2016054520A3 WO 2016054520 A3 WO2016054520 A3 WO 2016054520A3 US 2015053745 W US2015053745 W US 2015053745W WO 2016054520 A3 WO2016054520 A3 WO 2016054520A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell surface
surface proteins
engineered cell
effector cells
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/053745
Other languages
French (fr)
Other versions
WO2016054520A2 (en
Inventor
Chanhyuk KIM
Jennifer Ma
Eduardo LABORDA
Peter G. Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute for Biomedical Research
Original Assignee
California Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute for Biomedical Research filed Critical California Institute for Biomedical Research
Publication of WO2016054520A2 publication Critical patent/WO2016054520A2/en
Publication of WO2016054520A3 publication Critical patent/WO2016054520A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Disclosed herein are engineered cell surface proteins and effector cells expressing said engineered cell surface proteins. Further disclosed are methods of using the effector cells for the treatment of disease or condition in a subject in need thereof.
PCT/US2015/053745 2014-10-03 2015-10-02 Engineered cell surface proteins and uses thereof Ceased WO2016054520A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462059752P 2014-10-03 2014-10-03
US62/059,752 2014-10-03
US201562108947P 2015-01-28 2015-01-28
US62/108,947 2015-01-28

Publications (2)

Publication Number Publication Date
WO2016054520A2 WO2016054520A2 (en) 2016-04-07
WO2016054520A3 true WO2016054520A3 (en) 2016-05-19

Family

ID=55631764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/053745 Ceased WO2016054520A2 (en) 2014-10-03 2015-10-02 Engineered cell surface proteins and uses thereof

Country Status (1)

Country Link
WO (1) WO2016054520A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US20230302051A1 (en) * 2015-02-27 2023-09-28 Icell Gene Therapeutics Inc. CHIMERIC ANTIGEN RECEPTORS (CARs), TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOF
CA2986254A1 (en) 2015-05-18 2016-11-24 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP7217970B2 (en) 2016-10-07 2023-02-06 ティーシーアール２ セラピューティクス インク． Compositions and methods for reprogramming T-cell receptors using fusion proteins
KR20230172612A (en) 2016-10-19 2023-12-22 더 스크립스 리서치 인스티튜트 Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
CN110177803A (en) 2016-11-22 2019-08-27 T细胞受体治疗公司 For using fusion protein to carry out the composition and method that TCR is reprogramed
WO2018132506A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
CN110582509A (en) * 2017-01-31 2019-12-17 诺华股份有限公司 Cancer treatment with multispecific chimeric T cell receptor proteins
CN110612119B (en) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） Phosphatidylether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288B (en) 2017-02-28 2024-09-20 恩多塞特公司 Compositions and methods for CAR T cell therapy
WO2018170458A1 (en) 2017-03-16 2018-09-20 The General Hospital Corporation Chimeric antigen receptors targeting cd37
BR112020014913A2 (en) 2018-01-22 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) METHODS FOR USE OF T CAR CELLS
BR112020015884A2 (en) 2018-02-06 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) FLUORESCEINE SPECIFIC CHEMICAL ANTIGEN RECEIVERS (CARS) DISPLAYING THE GREAT T-CELL FUNCTION AGAINST FL-PLE MARKED TUMORS
EP3755366A4 (en) 2018-02-23 2021-12-29 Endocyte, Inc. Sequencing method for car t cell therapy
CN112469440B (en) * 2018-06-18 2024-09-06 优瑞科生物技术公司 Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
CN110872356B (en) * 2018-09-03 2023-06-13 广西慧宝源健康产业有限公司 Bispecific antibodies and methods of use thereof
CN109096404B (en) * 2018-09-13 2020-05-19 新乡医学院 Chimeric co-stimulatory transduction receptor, coding gene, recombinant expression vector, anti-tumor NK cell, and preparation method and application thereof
CN109280087B (en) * 2018-10-17 2020-05-15 新乡医学院 A dual-targeting switch receptor, encoding gene, recombinant expression vector, anti-tumor NK cell and preparation method and application thereof
CN112480263A (en) * 2019-09-12 2021-03-12 普米斯生物技术(苏州)有限公司 Design and application of dual-specificity T cell activator activated T cell
EP4126962A1 (en) * 2020-04-01 2023-02-08 Medigene Immunotherapies GmbH Cd3-fusion protein and uses thereof
MX2023004130A (en) * 2020-10-09 2023-06-13 Fate Therapeutics Inc MODIFIED INDUCED PLURIPOTENT STEM CELL (IPSC) AND ACTIVATED IMMUNE EFFECTOR CELLS.
EP4373501A4 (en) * 2021-07-23 2025-06-04 Board of Regents, The University of Texas System CD3-EXPRESSING NATURAL KILLER CELLS WITH ENHANCED FUNCTION FOR ADOPTIVE IMMUNOTHERAPY
TWI863006B (en) * 2021-10-18 2024-11-21 美商凱特製藥公司 Signaling domains for chimeric antigen receptors
WO2024133052A1 (en) * 2022-12-19 2024-06-27 Universität Basel Vizerektorat Forschung T-cell receptor fusion protein
WO2025193475A1 (en) * 2024-03-14 2025-09-18 The Regents Of The University Of California Enhancing immune cell innate and adaptive responses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014011988A2 (en) * 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody
US20140120622A1 (en) * 2012-10-10 2014-05-01 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2014190273A1 (en) * 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014011988A2 (en) * 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody
US20140120622A1 (en) * 2012-10-10 2014-05-01 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2014190273A1 (en) * 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YANKELEVICH, M ET AL.: "Anti- CD 3 x Anti-GD2 Bispecific Antibody Redirects T- Cell Cytolytic Activity to Neuroblastoma Targets.", PEDIATRIC BLOOD & CANCER., vol. 59, no. 7, 15 December 2012 (2012-12-15), pages 1198 - 1205 *

Also Published As

Publication number Publication date
WO2016054520A2 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
WO2016054520A3 (en) Engineered cell surface proteins and uses thereof
EP3229586A4 (en) Genetically modified cells, tissues, and organs for treating disease
EP3775228A4 (en) Engineered immune effector cells and use thereof
EP3215603A4 (en) Engineered three-dimensional skin tissues, arrays thereof, and methods of making the same
WO2015195483A3 (en) Graphene and graphene-related materials for manipulation of cell membrane potential
EP3204488A4 (en) Engineered renal tissues, arrays thereof, and methods of making the same
EP3065777A4 (en) Methods of use for il-22 in the treatment of gastrointestinal graft vs. host disease
WO2016097370A3 (en) Anti-axl antagonistic antibodies
KR102314045B9 (en) Composite positive electrode active material, manufacturing method thereof, positive electrode and lithium battery including the same
WO2016025454A3 (en) Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
WO2016004389A3 (en) Monovalent binding proteins
EP3114214A4 (en) Improved reprogramming methods and cell culture platforms
EP3189152A4 (en) Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
IL268354A (en) Microbial cells, methods of producing the same, and uses thereof
EP3538551A4 (en) Cd46-specific effector cells and uses thereof
EP3350866A4 (en) Solid electrolyte material and method for preparing the same, solid electrolyte and battery
EP3294128A4 (en) Biosensor electrode structure and biosensor including the same
EP3093339A4 (en) Stem cells derived from pure chorionic trophoblast layer and cell therapy comprising same
EP3073558A4 (en) Titanium material or titanium alloy material having surface conductivity, production method therefor, fuel cell separator using same, and fuel cell
WO2015058132A3 (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses
EP3098885A4 (en) Titanium material or titanium alloy material that have surface conductivity, fuel cell separator using same, and fuel cell
EP3265556A4 (en) Methods for making neural stem cells and uses thereof
EP3227429A4 (en) Cell and tissue culture container
EP3105687A4 (en) Biomedical research database development and uses
EP3288570A4 (en) Modified stem cells and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15845626

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15845626

Country of ref document: EP

Kind code of ref document: A2